Phase 3b data show centanafadine reduces adult ADHD and comorbid anxiety.
|Videos|July 12, 2021
Is That ADHD Treatment Working?
Author(s)Perry Roy, MD
A new combination of subjective and objective measures might finally provide a reliable answer.
Advertisement
It can be difficult to know if treatments for attention-deficit/hyperactivity disorder are having the desired effects. This is in part because clinical procedures commonly rely on self-rated scales and interviews. Could a more objective measurement be added into the mix?
In this Mental Health Minute, Dr Roy discusses the results of
Dr Roy is board certified in internal medicine and pediatrics. He specializes in treating ADHD.
Advertisement
Related to this article
Early trial shows investigational orexin-2 agonist ALKS 7290 improves adult ADHD symptoms in 14 days, with tolerable safety, paving way for phase 2.
Open-label extension data show fasedienol appears well tolerated and steadily improves social anxiety scores with as-needed intranasal use, as Vistagen plans FDA discussions.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Defining Treatment-Resistant Depression In Adults
2
Interventional Options for TRD: ECT, TMS, and Esketamine
3
AI as a Task-Replacing Tool for Psychiatric Care: A Conversation With Christoph Correll, MD
4
ARFID: When Remission Is Not Silence
5